Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2007-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7a43b7a7edc89083118c83d35b96843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea03b1a9451dee9ca16bee877060dd0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfa4b1108fa6827b4b7e84b55403c18a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9abcec3cddc4a94b46567c857bfbecf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_304ad33ce32380cf6ef8d1d86350bb3f |
publicationDate |
2009-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2023937-A2 |
titleOfInvention |
Rnai modulation of aha and therapeutic uses thereof |
abstract |
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell. |
priorityDate |
2006-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |